Abstract:Autoimmune bullous skin disorders are rare but meaningful chronic inflammatory diseases, many of which had a poor or devastating prognosis prior to the advent of immunosuppressive drugs such as systemic corticosteroids, which down-regulate the immune pathogenesis in these disorders. Glucocorticoids and adjuvant immunosuppressive drugs have been of major benefit for the fast control of most of these disorders, but their long-term use is limited by major side effects such as blood cytopenia, osteoporosis, diabetes mellitus, hypertension, and gastrointestinal ulcers. In recent years, major efforts were made to identify key elements in the pathogenesis of autoimmune bullous disorders, leading to the identification of their autoantigens, which are mainly located in desmosomes (pemphigus) and the basement membrane zone (pemphigoids). In the majority of cases, immunoglobulin G, and to a lesser extent, immunoglobulin A autoantibodies directed against distinct cutaneous adhesion molecules are directly responsible for the loss of cell-cell and cell-basement membrane adhesion, which is clinically related to the formation of blisters and/or erosions of the skin and mucous membranes. We describe and discuss novel therapeutic strategies that directly interfere with the production and regulation of pathogenic autoantibodies (rituximab), their catabolism (intravenous immunoglobulins), and their presence in the circulation and extravascular tissues such as the skin (immunoadsorption), leading to a significant amelioration of disease. Moreover, we show that these novel therapies have pleiotropic effects on various proinflammatory cells and cytokines. Recent studies in bullous pemphigoid suggest that targeting of immunoglobulin E autoantibodies (omalizumab) may be also beneficial. In summary, the introduction of targeted therapies in pemphigus and pemphigoid holds major promise because of the high efficacy and fewer side effects compared with conventional global immunosuppressive therapy.

[Pemphigus: current and future treatment strategies]

Immunotherapy for Pemphigus: Present and Future

Treatment of bullous pemphigoid and pemphigus. The French experience, 2009 update

Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy

Seeking approval: present and future therapies for pemphigus vulgaris.

Immunosuppressive adjuvant therapy for pemphigus

Pemphigoid diseases in patients with end-stage kidney diseases: pathogenesis and treatment

Beyond The Skin: B Cells in Pemphigus Vulgaris, Tolerance and Treatment

A Comprehensive Review on the Efficacy of Anti-CD20 Therapies in Pemphigus Treatment

Adjuvant therapy for pemphigus in addition to glucocorticoid and immunosuppressor

[Bullous pemphigoid: diagnostics and new therapeutic strategies]

Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid

Pemphigus relapse: Mechanisms, risk factors, and agents associated with disease recurrence

Bullous Pemphygoid and Novel Therapeutic Approaches

Diagnosis and treatment of patients with autoimmune bullous disorders in Germany

Targeted Therapies for Autoimmune Bullous Diseases: Current Status

Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations

[The mosaic of pemphigus]

[Treatment of ocular mucous membrane pemphigoid]

Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options

Oral pemphigus vulgaris diagnostic characteristics and treatment: a systematic review